Stewart Fisher - 08 Dec 2021 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Scientific Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
08 Dec 2021
Net transactions value
+$73,000
Form type
4
Filing time
10 Dec 2021, 15:30:26 UTC
Previous filing
05 Aug 2021
Next filing
16 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Options Exercise $5,007 +2,373 +10% $2.11 25,117 08 Dec 2021 Direct
transaction CCCC Common Stock Options Exercise $65,986 +17,786 +71% $3.71 42,903 08 Dec 2021 Direct
transaction CCCC Common Stock Options Exercise $2,007 +403 +0.94% $4.98 43,306 08 Dec 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -2,373 -100% $0.000000* 0 08 Dec 2021 Common Stock 2,373 $2.11 Direct F1
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -17,786 -32% $0.000000 37,728 08 Dec 2021 Common Stock 17,786 $3.71 Direct F2
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -403 -0.2% $0.000000 203,994 08 Dec 2021 Common Stock 403 $4.98 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested and exercisable as of the date hereof.
F2 20% of this option vested and became exercisable on May 1, 2019, with the remainder vesting in 16 equal quarterly installments thereafter.
F3 This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020.